<p>Ranbaxy said it has entered into a strategic in-licensing agreement with Medy-Tox Inc and the introduction of the product would strengthen the company's presence in the dermatological segment.<br /><br />In India, the current market size for this drug is about Rs 30 crore per annum.<br /><br />"Neuronox comes as a welcome alternative to dermatologists in India and we aim to make botulinum toxin therapy more accessible and affordable to people in the country," Ranbaxy's Senior Vice President & Regional Director -- Asia & CIS -- Sanjeev Dani said in a statement.<br /><br />Shares of Ranbaxy were trading at Rs 358.25, up 0.90 per cent, in the afternoon trade on the Bombay Stock Exchange.</p>
<p>Ranbaxy said it has entered into a strategic in-licensing agreement with Medy-Tox Inc and the introduction of the product would strengthen the company's presence in the dermatological segment.<br /><br />In India, the current market size for this drug is about Rs 30 crore per annum.<br /><br />"Neuronox comes as a welcome alternative to dermatologists in India and we aim to make botulinum toxin therapy more accessible and affordable to people in the country," Ranbaxy's Senior Vice President & Regional Director -- Asia & CIS -- Sanjeev Dani said in a statement.<br /><br />Shares of Ranbaxy were trading at Rs 358.25, up 0.90 per cent, in the afternoon trade on the Bombay Stock Exchange.</p>